Dimebolin dihydrochloride, dimebolin (hydrochloride), also known as Dimebon ™, is an orally-available drug, approved in Russia for use as a non-selective antihistamine, that has shown promise in the treatment of neurodegenerative diseases, including Alzheimer′s disease and Huntington′s disease. In addition to preventing the onset and progression of disease by being neuroprotective, Dimebolin appears to promote clinical improvement by increasing cognitive function. At the cellular level, Dimebolin appears to have diverse effects, inhibiting the neurotoxic action of β-amyloid and acting as a calcium channel protein inhibitor, inhibiting NMDA-type glutamate receptors, and preventing mitochondrial leakage. The hydrochloride form of Dimebolin is soluble in both aqueous and organic solvents.
1 Lermontova, N.N., Lukoyanov, N.V., Serkova, T.P., et al. Dimebon improves learning in animals with experimental Alzheimer′s disease. Bulletin of Experimental Biology and Medicine 129(6) 640-642 (2000). 2 Doody, R.S., Gavrilova, S.I., Sano, M., et al.